UK-based pharmaceutical company Medeva has entered into a deal withPeptide Therapeutics to transfer to PT intellectual property rights primarily relating to non-injectable vaccine delivery technology. PT will pay Medeva L1 million ($1.6 million) on completion. A further payment of L1 million will be made in respect of Medeva carrying out certain development work over a two-year period. Medeva has also agreed to subscribe L3 million for 882,353 new ordinary shares in PT at a price of L3.40 per share.
Under the terms of the agreement, PT will utilize this technology to pursue the research and early-stage development of a number of projects in this area. Medeva will have an option to take up the rights to complete development and commercialize products arising from these development programs.
PT will pursue the development to proof-of-principle stage of enterotoxigenic E coli, typhoid, and intranasal influenza vaccines. Administration routes will be oral and nasal. Development programs will be overseen by a committee consisting of representatives from both Medeva and PT.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze